Quantcast

Latest Monoclonal antibodies Stories

2014-10-29 16:28:36

Payers Employ a Variety of Cost-Control Measures to Manage the Utilization of Premium-Priced RA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 29, 2014 /PRNewswire/ -- Decision Resources Group finds that although 80 percent of surveyed rheumatologists currently prescribe Pfizer's Xeljanz for the treatment of rheumatoid arthritis (RA), it is usually used in later lines of therapy. Physicians most frequently cite limited formulary coverage and reimbursement...

2014-10-29 08:32:46

DUBLIN, Oct. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global and China Monoclonal Antibody Industry Report, 2014-2019" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biotech drugs with the fastest CAGR in recent years. Global...

2014-10-28 16:27:34

Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD) MONROVIA, Calif., Oct. 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has regained all development and commercial rights to XmAb(®)5871 by seeking and obtaining a termination of the prior option and...

2014-10-27 20:22:39

LA JOLLA, Calif., and JUPITER, Fla., Oct. 27, 2014 /PRNewswire-USNewswire/ -- Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute (TSRI). According to results released today from a Phase 2 study of 199 patients with active, moderate to severe disease, the drug candidate RPC1063 has potential to significantly improve the treatment paradigm for ulcerative colitis patients....

2014-10-23 00:21:29

Ebola detection kits for humans and animals are now possible using ADI antibody or antigen ELISA kits with results in less than 2 hours. Ebola Rapid test cards, similar to pregnancy tests, have also been developed that provide results in 2-10 mins. SAN ANTONIO, Oct. 22, 2014 /PRNewswire/ -- San Antonio, Texas-based Biotech Company Alpha Diagnostic Int'l (ADI) has developed and released several convenient, rapid, and sensitive ELISA test kits for the detection of major Ebola viral...

2014-10-22 16:28:34

Broad Bi-Specific Antibody Collaboration Now Includes Targets that Could Lead to New Cancer Immunotherapies INDIANAPOLIS and VANCOUVER, Oct. 22, 2014 /CNW/ - Zymeworks Inc. and Eli Lilly and Company (NYSE: LLY) today announced the expansion of their existing licensing and collaboration agreement. Originally announced in January 2014, the global strategic collaboration is focused on the development of an undisclosed number of novel bi-specific antibody therapeutics using Zymeworks'...

2014-10-21 23:09:47

ChinaMarketResearchReports.com adds Latest Report on “Global and China Monoclonal Antibody Industry Report, 2014-2019” to its store. Inquire for discount on this report at http://www.chinamarketresearchreports.com/contacts/inquiry.php?name=114942 Dallas, TX (PRWEB) October 21, 2014 Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biotech...

2014-10-21 08:34:56

Management Responds To Inquiries Concerning Discovery Capabilities For Anti-Ebola Treatments SAN DIEGO, Oct. 21, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company, announced today that it has formally nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer. The fully human antibody, recovered from patients undergoing cancer vaccine treatment at...

2014-10-21 08:32:32

PLYMOUTH MEETING, Pa., Oct. 21, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca. The group will develop DNA-based monoclonal antibodies...

2014-10-20 08:31:57

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Marco Londei, M.D. as Chief Development Officer. Dr. Londei will lead the preclinical and clinical development of AnaptysBio's proprietary antibody pipeline. http://photos.prnewswire.com/prnvar/20111205/SF16052LOGO "We are pleased to welcome Dr. Londei to AnaptysBio's executive leadership team," said Hamza Suria,...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related